Outpace Bio

United States - Seattle, Washington

• 02/08/2024
• Series B
• $144,000,000

Outpace is creating cell therapies with curative potential through protein design and cellular engineering. With an initial focus on solid tumors, Outpace is developing technologies that overcome the barriers to efficacy and safety by programming cells to make the right decisions inside patients. Outpace’s suite of technologies drive persistent activity of the cell therapy (OutLast™), recruit a productive immune response in the tumor microenvironment (OutSmart™), and achieve the potency (OutSpacers™), specificity (Co-LOCKR™), and safety (EGFRopt™) necessary to unlock diverse cancer indications. Outpace’s internal and partnered pipeline approach is optimized for rapid clinical validation of its technologies across diverse cell types and manufacturing processes.

At Outpace Bio, we believe that the highest performing teams include people from a wide variety of backgrounds and experiences who respectfully challenge each other. We are committed to building an open, diverse, and inclusive culture for all employees.

Related People

Marc LajoieCo Founder

United States - Seattle, Washington

Leading a team at Outpace Bio combining protein design with cell engineering to unlock the future of curative cell therapies.

PhD in chemical biology with a focus on genome engineering and the genetic code (George Church lab). Postdoc in protein design developing computationally designed drug delivery devices and protein logic (David Baker lab).

Specialties: T cell therapies, protein design, synthetic biology, genome design, genome engineering, next generation DNA sequencing, next generation gene synthesis

LinkedIn https://www.linkedin.com/in/marclajoie/